Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

Novartis Pharmaceuticals396 enrolled

Overview

This study will evaluate the safety and efficacy of FTY720 combined with cyclosporine and corticosteroids in patients receiving a kidney transplant.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

396

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria \- Completion of Core study Exclusion Criteria Other protocol-defined exclusion criteria may apply.

IA, IB, IIA, IIB or III diagnosed by biopsy according to Banff 97 criteria within 36 months post transplant

Permanent resumption of dialysis within 36 months post transplant

Surgical removal of graft within 36 months post transplant

Death within 36 months post transplant

Discontinuation within 36 months post transplant

FEV1 , FVC, DLCO within 36 months post transplant

Serum creatinine and estimated creatinine clearance within 36 months post transplant

Absolute lymphocyte count within 36 months post transplant

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.